Xarelto for CAD/PAD? LVAD Cord Out the Head; HDL Drug Moves Forward
Recent developments of interest in cardiovascular medicine
Based on the COMPASS trial results, the ultra-low 2.5-mg twice-daily dose of rivaroxaban (Xarelto) has been submitted for a supplemental indication in prevention of major cardiovascular events in coronary artery disease or peripheral artery disease patients as well as prevention of acute limb ischemia in the latter, drugmaker Janssen announced.